Idelalisib – Uses, Dosage, Side Effects, Interation Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma, and indolent non-Hodgkin lymphoma. Idelalisib is associated with a high rate of serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal. Idelalisib is an orally bioavailable, small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. Idelalisib is a member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for the treatment of refractory indolent non-Hodgkin’s lymphoma and relapsed chronic lymphocytic leukemia. It has a role as an antineoplastic agent, an apoptosis inducer, and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is a member of purines, an organofluorine compound, a member of quinazolines, an aromatic amine, and a secondary amino compound. Mechanism of Action Idelalisib specifically inhibits P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. or Idelalisib is an inhibitor of PI3Kdelta kinase, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of chemotaxis and adhesion, and reduced cell viability. Indications Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma and indolent non-Hodgkin lymphoma. Idelalisib is an antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,[rx] idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.[rx] It appears to be effective and leads to improvement of lymphadenopathy and splenomegaly. However, the lymphocyte counts take longer to decrease to normal levels with idelalisib. It is not recommended as a first-line treatment.[rx] It is also approved for the treatment of follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), both in patients who have received at least two prior systemic therapies.[rx] In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies. The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies. Relapsed Chronic Lymphocytic Leukemia Relapsed Small Lymphocytic Lymphoma Relapsed follicular B-cell non-Hodgkin’s lymphoma Use in Cancer Idelalisib is approved to treat: Chronic lymphocytic leukemia (CLL) that has relapsed (come back). It is used with rituximab in patients who may be treated with rituximab alone due to other health problems. Idelalisib is also being studied in the treatment of other types of cancer. Contraindications a bad infection decreased blood platelets low levels of a type of white blood cell called neutrophils a type of inflammation of the lung called interstitial pneumonitis a hole in the intestine liver problems high amount of bilirubin in the blood diarrhea abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding progressive multifocal leukoencephalopathy, a type of brain infection Dosage Strengths: 100 mg; 150 mg Non-Hodgkin’s Lymphoma 150 mg orally 2 times a day until disease progression or unacceptable toxicity This drug can be taken with or without food. Tablets should be swallowed whole. If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. Chronic Lymphocytic Leukemia 150 mg orally 2 times a day until disease progression or unacceptable toxicity This drug can be taken with or without food. Tablets should be swallowed whole. If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. Lymphoma 150 mg orally 2 times a day until disease progression or unacceptable toxicity This drug can be taken with or without food. Tablets should be swallowed whole. If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take the missed dose as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. The treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least 2 prior systemic therapies. The treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least 2 prior systemic therapies. Liver Dose Adjustments AST and/or ALT greater than 3 to 5 times the upper limit of normal (3 to 5 x ULN): Maintain dose, monitor at least weekly until less than or equal to ULN. AST and/or ALT greater than 5 to 20 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day. AST and/or ALT greater than 20 x ULN: Permanently discontinue therapy. Bilirubin greater than 1.5 to 3 x ULN: Maintain dose, monitor at least weekly until less than or equal to ULN. Bilirubin greater than 3 to 10 x ULN: Withhold therapy, monitor at least weekly until less than or equal to ULN, may resume at 100 mg twice a day. Bilirubin greater than 10 x ULN: Permanently discontinue therapy. Dose Adjustments Pneumonitis: Discontinue therapy in patients with any severity of symptomatic pneumonitis. Diarrhea: If moderate diarrhea develops during therapy (increase of 4 to 6 stools per day over baseline), maintain dose and monitor at least weekly until resolved. If severe diarrhea develops during therapy (increase of 7 or more stools per day over baseline), withhold therapy and monitor at least weekly until resolved, then resume therapy at 100 mg twice a day. If life-threatening diarrhea develops during treatment, discontinue therapy permanently. Neutropenia: ANC 1 to less than 1.5 Gi/L: Maintain dose. ANC 0.5 to less than 1 Gi/L: Maintain dose and monitor ANC at least weeky. ANC less than 0.5: interrupt therapy and monitor at least weekly until ANC is 0.5 Gi/L or greater, then resume therapy at 100 mg twice a day. Thrombocytopenia: Platelets 50 to less than 75 Gi/L: Maintain dose. Platelets 25 to less than 50 Gi/L: Maintain dose and monitor platelet counts at least weekly. Platelets less than 25 Gi/L: Withhold therapy and monitor at least weekly; resume therapy at 100 mg twice a day when platelets are 25 Gi/L or greater. Infections: Grade 3 or higher sepsis or pneumonia: Interrupt therapy until infection has resolved. Evidence of CMV infection or viremia: Interrupt therapy in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved. If therapy is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly. Evidence of PJP infection: Interrupt therapy in patients with suspected PJP infection of any grade. Permanently discontinue therapy if PJP infection is confirmed. Lymphocytosis: No dose modification is required for lymphocytosis, which has been observed in some patients taking this drug. This lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings. FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION: Fatal and/or serious hepatotoxicity occurred in 16% to 18% of patients. Monitor hepatic function prior to and during therapy. Interrupt therapy and then reduce or discontinue the drug as recommended. Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of patients. Monitor for development of severe diarrhea or colitis. Interrupt therapy and then reduce or discontinue the drug as recommended. Fatal and/or serious pneumonitis occurred in 4% of patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt therapy and then reduce or discontinue the drug as recommended. Fatal and/or serious infections occurred in 21% to 48% of patients. Monitor for infection. Interrupt therapy if infection is suspected. Fatal and serious intestinal perforation can occur. Discontinue therapy for intestinal perforation. Administration advice: Take with or without food. Tablets should be swallowed whole. Side Effects The Most Common headache difficulty falling asleep or staying asleep decreased appetite increased thirst heartburn joint pain night sweats lack of energy swelling of the hands, feet, ankles, or lower legs red, itching, peeling, or blistering skin painful sores or ulcers on your skin, lips, or in your mouth difficulty swallowing or breathing; swelling of the face, lips, or throat; hives; itching Bloating or swelling of the face, arms, hands, lower legs, or feet decreased appetite difficulty with moving muscle pain or stiffness night sweats pain in the joints rapid weight gain tingling of the hands or feet trouble sleeping unusual weight gain or loss More common Black, tarry stools body aches or pain chest tightness chills clay colored stools confusion cough cough producing mucus dark urine decreased appetite difficulty with breathing dizziness ear congestion fainting fast heartbeat fever headache itching or skin rash lightheadedness loss of appetite loss of voice lower back or side pain nausea and vomiting pain pain or tenderness around the eyes and cheekbones painful or difficult urination pale skin rapid, shallow breathing sneezing sore throat stomach cramps, pain, or tenderness stuffy or runny nose swelling of the feet or lower legs trouble breathing ulcers, sores, or white spots in the mouth unusual bleeding or bruising unusual tiredness or weakness watery or bloody diarrhea yellow eyes or skin Rare Bladder pain bloody or cloudy urine difficult, burning, or painful urination frequent urge to urinate lower back or side pain Blistering, peeling, or loosening of the skin chest pain cracks in the skin difficulty with swallowing general feeling of discomfort or illness heartburn hives indigestion joint or muscle pain loss of heat from the body puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue red skin lesions, often with a purple center red, irritated eyes red, swollen skin scaly skin severe abdominal or stomach pain, cramping, or burning thickening of bronchial secretions vomiting of material that looks like coffee grounds, severe and continuing Drug Interactions DRUG INTERACTION Abametapir The serum concentration of Idelalisib can be increased when it is combined with Abametapir. Abatacept The metabolism of Idelalisib can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Idelalisib. Abrocitinib The serum concentration of Idelalisib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Idelalisib can be decreased when combined with Acalabrutinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Idelalisib. Acetaminophen The metabolism of Idelalisib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Idelalisib can be decreased when combined with Acetazolamide. Adalimumab The metabolism of Idelalisib can be increased when combined with Adalimumab. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Idelalisib. Afatinib Afatinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Albendazole The metabolism of Idelalisib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Idelalisib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Idelalisib. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Idelalisib. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Idelalisib. Alpelisib The metabolism of Idelalisib can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Idelalisib. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Idelalisib. Ambrisentan The serum concentration of Idelalisib can be increased when it is combined with Ambrisentan. Aminoglutethimide The metabolism of Idelalisib can be increased when combined with Aminoglutethimide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Idelalisib. Amiodarone The metabolism of Idelalisib can be decreased when combined with Amiodarone. Amobarbital The metabolism of Idelalisib can be increased when combined with Amobarbital. Amprenavir The metabolism of Idelalisib can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Idelalisib. Anakinra The metabolism of Idelalisib can be increased when combined with Anakinra. Anifrolumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Anifrolumab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Idelalisib. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Idelalisib. Antilymphocyte The risk or severity of adverse effects can be increased when Idelalisib is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib. Apalutamide The serum concentration of Idelalisib can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Idelalisib can be increased when it is combined with Apixaban. Apremilast The metabolism of Idelalisib can be increased when combined with Apremilast. Aprepitant The metabolism of Idelalisib can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Idelalisib. Aripiprazole The metabolism of Aripiprazole lauroxil can be decreased when combined with Idelalisib. Armodafinil The metabolism of Idelalisib can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idelalisib. Articaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Articaine. Asciminib The serum concentration of Idelalisib can be increased when it is combined with Asciminib. Asenapine The metabolism of Asenapine can be decreased when combined with Idelalisib. Astemizole The metabolism of Idelalisib can be decreased when combined with Astemizole. AstraZeneca The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Idelalisib. Asunaprevir The metabolism of Idelalisib can be increased when combined with Asunaprevir. Atazanavir The metabolism of Idelalisib can be decreased when combined with Atazanavir. Atogepant The serum concentration of Atogepant can be increased when it is combined with Idelalisib. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Idelalisib. Avacopan The metabolism of Idelalisib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Idelalisib. Avatrombopag Avatrombopag may decrease the excretion rate of Idelalisib which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Idelalisib. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Idelalisib. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Idelalisib. Azithromycin The metabolism of Idelalisib can be decreased when combined with Azithromycin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Idelalisib. Bacillus antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Idelalisib. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Idelalisib. Baricitinib The risk or severity of adverse effects can be increased when Idelalisib is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Idelalisib. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Idelalisib. Beclomethasone The metabolism of Idelalisib can be increased when combined with Beclomethasone dipropionate. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Idelalisib. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Idelalisib. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Idelalisib. Belumosudil The risk or severity of adverse effects can be increased when Idelalisib is combined with Belumosudil. Belzutifan The serum concentration of Idelalisib can be decreased when it is combined with Belzutifan. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Idelalisib. Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Idelalisib. Benzocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Idelalisib. Berotralstat The serum concentration of Idelalisib can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Idelalisib can be increased when combined with Betamethasone. Betamethasone The metabolism of Idelalisib can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Idelalisib. Bexarotene The metabolism of Idelalisib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Idelalisib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Idelalisib can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Idelalisib can be increased when combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Idelalisib. Bisoprolol The serum concentration of Idelalisib can be increased when it is combined with Bisoprolol. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Idelalisib. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Idelalisib. Boceprevir The metabolism of Idelalisib can be decreased when combined with Boceprevir. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Idelalisib. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Idelalisib. Bosentan The metabolism of Idelalisib can be increased when combined with Bosentan. Bosutinib The metabolism of Idelalisib can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Idelalisib can be decreased when combined with Brentuximab vedotin. Brigatinib The metabolism of Brigatinib can be decreased when combined with Idelalisib. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Idelalisib. Brodalumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Brodalumab. Budesonide The metabolism of Idelalisib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Bupivacaine. You Might Also Read Russian Mineral Oil - Uses, Dosage, Side Effects, Interactions Buprenorphine The metabolism of Idelalisib can be decreased when combined with Buprenorphine. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Idelalisib. Butacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Butacaine. Butalbital The metabolism of Idelalisib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idelalisib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Idelalisib. Caffeine Caffeine may decrease the excretion rate of Idelalisib which could result in a higher serum level. Calcitriol The metabolism of Idelalisib can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Idelalisib can be increased when combined with Canakinumab. Candicidin The metabolism of Idelalisib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Idelalisib can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Idelalisib. Capmatinib The serum concentration of Capmatinib can be increased when it is combined with Idelalisib. Capsaicin The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Capsaicin. Carbamazepine The metabolism of Idelalisib can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Idelalisib. Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Idelalisib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Idelalisib. Carvedilol The serum concentration of Idelalisib can be increased when it is combined with Carvedilol. Caspofungin The excretion of Caspofungin can be decreased when combined with Idelalisib. Cefradine The metabolism of Idelalisib can be increased when combined with Cefradine. Cenobamate The serum concentration of Idelalisib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Idelalisib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Idelalisib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Idelalisib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Idelalisib can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Idelalisib. Chloramphenicol The metabolism of Idelalisib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Chloroprocaine. Chlorpromazine The metabolism of Idelalisib can be increased when combined with Chlorpromazine. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Idelalisib. Cholesterol Cholesterol may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Idelalisib. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Idelalisib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Idelalisib. Cimetidine The metabolism of Idelalisib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Cinchocaine. Ciprofloxacin The metabolism of Idelalisib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Idelalisib can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib. Citalopram The metabolism of Idelalisib can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Idelalisib. Clarithromycin The metabolism of Idelalisib can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Idelalisib can be increased when combined with Clevidipine. Clindamycin The metabolism of Clindamycin can be decreased when combined with Idelalisib. Clobazam The metabolism of Idelalisib can be increased when combined with Clobazam. Clobetasol The metabolism of Idelalisib can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Idelalisib. Clofazimine The metabolism of Idelalisib can be decreased when combined with Clofazimine. Clofibrate The metabolism of Idelalisib can be increased when combined with Clofibrate. Clomifene The serum concentration of Idelalisib can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Idelalisib. Clonidine The metabolism of Clonidine can be decreased when combined with Idelalisib. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idelalisib. Clozapine The metabolism of Idelalisib can be increased when combined with Clozapine. Cobicistat The metabolism of Idelalisib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Idelalisib can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Idelalisib. Conivaptan The metabolism of Idelalisib can be decreased when combined with Conivaptan. Cestrogens The excretion of Conjugated estrogens can be decreased when combined with Idelalisib. Copanlisib The metabolism of Copanlisib can be decreased when combined with Idelalisib. Corticotropin The metabolism of Idelalisib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Idelalisib can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idelalisib. Crizotinib The metabolism of Idelalisib can be decreased when combined with Crizotinib. Curcumin The metabolism of Idelalisib can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Idelalisib can be increased when combined with Cyclophosphamide. Cyclosporine Idelalisib may increase the immunosuppressive activities of Cyclosporine. Cyproheptadine The metabolism of Cyproheptadine can be decreased when combined with Idelalisib. Cyproterone acetate The metabolism of Idelalisib can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Idelalisib. Dabigatran etexilate The serum concentration of Idelalisib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Idelalisib can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idelalisib. Daclatasvir Daclatasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Idelalisib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idelalisib. Dalfopristin The metabolism of Idelalisib can be decreased when combined with Dalfopristin. Danazol The metabolism of Idelalisib can be decreased when combined with Danazol. Daptomycin The serum concentration of Idelalisib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idelalisib. Darolutamide The serum concentration of Idelalisib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Idelalisib can be increased when it is combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Dasatinib The metabolism of Idelalisib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Idelalisib can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Idelalisib. Deferasirox The metabolism of Idelalisib can be increased when combined with Deferasirox. Deflazacort The metabolism of Idelalisib can be increased when combined with Deflazacort. Delavirdine The metabolism of Idelalisib can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib. Desipramine The metabolism of Idelalisib can be decreased when combined with Desipramine. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Idelalisib. Desvenlafaxine The metabolism of Idelalisib can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Idelalisib is combined with Deucravacitinib. Dexamethasone The metabolism of Idelalisib can be increased when combined with Dexamethasone. Dexamethasone The metabolism of Idelalisib can be increased when combined with Dexamethasone acetate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib. Dextropropoxyph The metabolism of Idelalisib can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Idelalisib can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Idelalisib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Idelalisib can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Idelalisib. Digoxin The serum concentration of Digoxin can be increased when it is combined with Idelalisib. Dihydroergocornine The metabolism of Idelalisib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Idelalisib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Idelalisib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Idelalisib can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Idelalisib. Dimethyl sulfoxide The metabolism of Idelalisib can be decreased when combined with Dimethyl sulfoxide. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Idelalisib. Dinutuximab The risk or severity of adverse effects can be increased when Idelalisib is combined with Dinutuximab. Diosmin The metabolism of Idelalisib can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Diphenhydramine. Diroximel fumarate The risk or severity of adverse effects can be increased when Idelalisib is combined with Diroximel fumarate. Docetaxel The metabolism of Idelalisib can be decreased when combined with Docetaxel. Dofetilide The metabolism of Dofetilide can be decreased when combined with Idelalisib. Dolutegravir The serum concentration of Idelalisib can be increased when it is combined with Dolutegravir. Doxazosin The metabolism of Idelalisib can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Idelalisib can be decreased when combined with Doxorubicin. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Idelalisib. Dronedarone The serum concentration of Idelalisib can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Idelalisib can be decreased when combined with Drospirenone. Duvelisib The metabolism of Idelalisib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Dyclonine. Ebastine The metabolism of Idelalisib can be decreased when combined with Ebastine. Ebola vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Idelalisib. Echinacea The metabolism of Idelalisib can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Idelalisib. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Idelalisib. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib. Efavirenz The metabolism of Idelalisib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Idelalisib can be increased when it is combined with Elagolix. Elbasvir Elbasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Elexacaftor The metabolism of Idelalisib can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Idelalisib. Eltrombopag Eltrombopag may decrease the excretion rate of Idelalisib which could result in a higher serum level. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Idelalisib. Elvitegravir The metabolism of Idelalisib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Idelalisib can be increased when combined with Emapalumab. Enalapril The excretion of Enalapril can be decreased when combined with Idelalisib. Enasidenib The metabolism of Idelalisib can be increased when combined with Enasidenib. Enfortumab The serum concentration of Enfortumab vedotin can be increased when it is combined with Idelalisib. Entrectinib The metabolism of Entrectinib can be decreased when combined with Idelalisib. Enzalutamide The serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Idelalisib can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Idelalisib. Erdafitinib The serum concentration of Idelalisib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Idelalisib can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Idelalisib. Erlotinib The metabolism of Idelalisib can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Idelalisib. Erythromycin The metabolism of Idelalisib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Idelalisib. Esketamine The metabolism of Idelalisib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Idelalisib can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Idelalisib can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Idelalisib can be decreased when combined with Estetrol. Estradiol Estradiol may decrease the excretion rate of Idelalisib which could result in a higher serum level. Estradiol acetate The metabolism of Idelalisib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Idelalisib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Idelalisib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Idelalisib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Idelalisib can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Idelalisib. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Idelalisib. Etanercept The metabolism of Idelalisib can be increased when combined with Etanercept. Ethambutol The metabolism of Idelalisib can be decreased when combined with Ethambutol. Ethanol The metabolism of Idelalisib can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Idelalisib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Idelalisib. Etoricoxib The metabolism of Idelalisib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Idelalisib can be increased when combined with Etravirine. Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Idelalisib. Ezetimibe The excretion of Ezetimibe can be decreased when combined with Idelalisib. Ezogabine The metabolism of Ezogabine can be decreased when combined with Idelalisib. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Idelalisib. Favipiravir The serum concentration of Idelalisib can be increased when it is combined with Favipiravir. Febuxostat The excretion of Idelalisib can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Felbamate The metabolism of Idelalisib can be increased when combined with Felbamate. Fenofibrate The metabolism of Idelalisib can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Idelalisib. Fexinidazole The metabolism of Idelalisib can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Idelalisib can be increased when it is combined with Fexofenadine. Filgotinib The risk or severity of adverse effects can be increased when Idelalisib is combined with Filgotinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Idelalisib. Fingolimod Idelalisib may increase the immunosuppressive activities of Fingolimod. Flibanserin The serum concentration of Idelalisib can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Idelalisib. Flucloxacillin The metabolism of Idelalisib can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Idelalisib can be decreased when combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Idelalisib. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Idelalisib. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Idelalisib. Flunisolide The metabolism of Idelalisib can be increased when combined with Flunisolide. Fluocinolone The metabolism of Idelalisib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Idelalisib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Idelalisib can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Idelalisib. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idelalisib. Fluoxetine The metabolism of Idelalisib can be decreased when combined with Fluoxetine. Fluprednisolone The risk or severity of adverse effects can be increased when Idelalisib is combined with Fluprednisolone. Fluticasone The metabolism of Idelalisib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Idelalisib can be increased when combined with Fluticasone furoate. Fluticasone The metabolism of Idelalisib can be decreased when combined with Fluticasone propionate. Fluvastatin The excretion of Fluvastatin can be decreased when combined with Idelalisib. Fluvoxamine The metabolism of Idelalisib can be decreased when combined with Fluvoxamine. Formestane The metabolism of Idelalisib can be increased when combined with Formestane. Fosamprenavir The metabolism of Idelalisib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Idelalisib can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Idelalisib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Idelalisib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Idelalisib can be decreased when combined with Fostamatinib. Fostemsavir Fostemsavir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Fusidic acid The metabolism of Idelalisib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Idelalisib. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Idelalisib. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Idelalisib. Gefitinib Gefitinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Idelalisib. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib. Gilteritinib The metabolism of Idelalisib can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Idelalisib can be decreased when combined with Ginkgo biloba. Glasdegib Glasdegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Idelalisib. Glecaprevir The metabolism of Idelalisib can be decreased when combined with Glecaprevir. Glyburide The metabolism of Idelalisib can be decreased when combined with Glyburide. Glycerol The metabolism of Idelalisib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Idelalisib can be increased when combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Griseofulvin The metabolism of Idelalisib can be increased when combined with Griseofulvin. Guselkumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Idelalisib. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Idelalisib. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Idelalisib. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Idelalisib. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Idelalisib. Hydralazine The metabolism of Idelalisib can be decreased when combined with Hydralazine. Hydrocortamate The metabolism of Idelalisib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Idelalisib can be increased when combined with Hydrocortisone. Hydrocortisone The metabolism of Idelalisib can be increased when combined with Hydrocortisone acetate. Hydrocortisone The metabolism of Idelalisib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Idelalisib can be increased when combined with Hydrocortisone succinate. Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Idelalisib. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Idelalisib. Hydroxyzine The metabolism of Hydroxyzine can be decreased when combined with Idelalisib. Ibritumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Idelalisib. Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Idelalisib. Ifosfamide The metabolism of Idelalisib can be increased when combined with Ifosfamide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Idelalisib. Imatinib The serum concentration of Idelalisib can be increased when it is combined with Imatinib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Idelalisib. Indacaterol The serum concentration of Idelalisib can be increased when it is combined with Indacaterol. Indinavir The metabolism of Idelalisib can be decreased when combined with Indinavir. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Idelalisib. Inebilizumab The risk or severity of infection can be increased when Idelalisib is combined with Inebilizumab. Infigratinib The metabolism of Idelalisib can be decreased when combined with Infigratinib. Infliximab The metabolism of Idelalisib can be increased when combined with Infliximab. You Might Also Read Eluxadoline Tablet - Uses, Dosage, Side Effects Ketazolam The metabolism of Idelalisib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Idelalisib can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Idelalisib can be decreased when combined with Lacosamide. Lamotrigine The metabolism of Lamotrigine can be decreased when combined with Idelalisib. Lanreotide The metabolism of Idelalisib can be decreased when combined with Lanreotide. Lansoprazole Lansoprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. Lapatinib The metabolism of Idelalisib can be decreased when combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Idelalisib. Lasmiditan The serum concentration of Idelalisib can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Lefamulin The serum concentration of Idelalisib can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Idelalisib is combined with Leflunomide. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Idelalisib. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Idelalisib. Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Idelalisib. Lesinurad The metabolism of Idelalisib can be increased when combined with Lesinurad. Letermovir The metabolism of Idelalisib can be decreased when combined with Letermovir. Levacetylmet The metabolism of Levacetylmethadol can be decreased when combined with Idelalisib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Idelalisib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Levobupivacaine. Levoketoconazole The metabolism of Idelalisib can be decreased when combined with Levoketoconazole. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Idelalisib. Lidocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Lidocaine. Linagliptin The metabolism of Idelalisib can be decreased when combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Idelalisib. Liothyronine The excretion of Liothyronine can be decreased when combined with Idelalisib. Liotrix The excretion of Liotrix can be decreased when combined with Idelalisib. Lomitapide The metabolism of Idelalisib can be decreased when combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Idelalisib. Lonafarnib The metabolism of Idelalisib can be decreased when combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Idelalisib. Loperamide The serum concentration of Idelalisib can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Idelalisib can be increased when it is combined with Lopinavir. Lorlatinib The metabolism of Idelalisib can be increased when combined with Lorlatinib. Losartan The metabolism of Idelalisib can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Idelalisib. Loxapine The serum concentration of Idelalisib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Idelalisib can be decreased when it is combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Idelalisib. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Idelalisib. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Idelalisib. Manidipine The metabolism of Idelalisib can be decreased when combined with Manidipine. Mannitol The serum concentration of Idelalisib can be increased when it is combined with Mannitol. Maribavir Maribavir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Mavacamten The serum concentration of Idelalisib can be decreased when it is combined with Mavacamten. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Idelalisib. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Idelalisib. Medroxyprogeste The metabolism of Idelalisib can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Idelalisib can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Idelalisib. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Idelalisib. Meperidine The metabolism of Idelalisib can be decreased when combined with Meperidine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Idelalisib. Meprednisone The metabolism of Idelalisib can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Idelalisib. Methadone The metabolism of Idelalisib can be decreased when combined with Methadone. Methimazole The metabolism of Idelalisib can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Idelalisib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Idelalisib. Methylene blue The metabolism of Idelalisib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Idelalisib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Idelalisib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Idelalisib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Idelalisib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Idelalisib can be decreased when combined with Methysergide. Metreleptin The metabolism of Idelalisib can be increased when combined with Metreleptin. Metronidazole The metabolism of Idelalisib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Idelalisib can be increased when combined with Metyrapone. Miconazole The metabolism of Idelalisib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Idelalisib. Midostaurin The metabolism of Idelalisib can be decreased when combined with Midostaurin. Mifepristone The metabolism of Idelalisib can be increased when combined with Mifepristone. Milnacipran The metabolism of Idelalisib can be decreased when combined with Milnacipran. Miocamycin The metabolism of Idelalisib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Idelalisib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Idelalisib can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Idelalisib can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Idelalisib. Mitotane The metabolism of Idelalisib can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Idelalisib. Mobocertinib The serum concentration of Idelalisib can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Idelalisib can be increased when combined with Modafinil. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Idelalisib. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Idelalisib. Mometasone fur The metabolism of Idelalisib can be increased when combined with Mometasone furoate. Monomethyl fum The risk or severity of adverse effects can be increased when Idelalisib is combined with Monomethyl fumarate. Morphine The serum concentration of Idelalisib can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Idelalisib can be decreased when combined with Mosunetuzumab. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Idelalisib. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib. Mycophenolate The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Idelalisib. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Idelalisib. Nafcillin The metabolism of Idelalisib can be increased when combined with Nafcillin. Naloxone The metabolism of Idelalisib can be decreased when combined with Naloxone. Natalizumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab. Nefazodone The metabolism of Idelalisib can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Idelalisib. Nelfinavir The metabolism of Idelalisib can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Idelalisib. Netupitant The metabolism of Idelalisib can be decreased when combined with Netupitant. Niacin The metabolism of Idelalisib can be decreased when combined with Niacin. Nicardipine The metabolism of Idelalisib can be decreased when combined with Nicardipine. Nilotinib The metabolism of Idelalisib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Idelalisib can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Idelalisib can be decreased when combined with Nintedanib. Norethisterone The metabolism of Idelalisib can be decreased when combined with Norethisterone. Norgestimate The metabolism of Idelalisib can be increased when combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Idelalisib. Noscapine The metabolism of Idelalisib can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Idelalisib which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Idelalisib. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Idelalisib. Ocrelizumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Ocrelizumab. Octreotide The serum concentration of Idelalisib can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Idelalisib. Olanzapine The metabolism of Olanzapine can be decreased when combined with Idelalisib. Olaparib The metabolism of Idelalisib can be decreased when combined with Olaparib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Idelalisib. Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Idelalisib. Omeprazole The metabolism of Idelalisib can be increased when combined with Omeprazole. Oritavancin The metabolism of Idelalisib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Idelalisib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Idelalisib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Idelalisib. Oteseconazole The serum concentration of Idelalisib can be increased when it is combined with Oteseconazole. Ouabain The excretion of Ouabain can be decreased when combined with Idelalisib. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib. Oxcarbazepine The metabolism of Idelalisib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Oxybuprocaine. Oxybutynin The metabolism of Idelalisib can be decreased when combined with Oxybutynin. Ozanimod The risk or severity of adverse effects can be increased when Idelalisib is combined with Ozanimod. Paclitaxel The metabolism of Idelalisib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Idelalisib can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Idelalisib can be decreased when combined with Palbociclib. Paliperidone The serum concentration of Idelalisib can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Idelalisib. Pantoprazole Pantoprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. Paricalcitol The metabolism of Paricalcitol can be decreased when combined with Idelalisib. Paritaprevir Paritaprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Pasireotide The metabolism of Idelalisib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Idelalisib can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib. Pegcetacoplan The risk or severity of adverse effects can be increased when Idelalisib is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Idelalisib. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idelalisib. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Idelalisib is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Idelalisib. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Idelalisib. Pentobarbital The metabolism of Idelalisib can be increased when combined with Pentobarbital. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Idelalisib. Perampanel The metabolism of Idelalisib can be increased when combined with Perampanel. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Idelalisib. Pexidartinib Idelalisib may increase the hepatotoxic activities of Pexidartinib. Phenobarbital The metabolism of Idelalisib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Idelalisib. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idelalisib. Phenylbutazone The metabolism of Idelalisib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Idelalisib can be increased when combined with Phenytoin. Pibrentasvir Pibrentasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Pimavanserin The metabolism of Idelalisib can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idelalisib. Pimozide The metabolism of Idelalisib can be decreased when combined with Pimozide. Piperaquine The metabolism of Idelalisib can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Idelalisib. Pitavastatin The excretion of Pitavastatin can be decreased when combined with Idelalisib. Pitolisant The serum concentration of Idelalisib can be decreased when it is combined with Pitolisant. Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Idelalisib. Ponatinib The risk or severity of adverse effects can be increased when Ponatinib is combined with Idelalisib. Ponesimod The risk or severity of adverse effects can be increased when Idelalisib is combined with Ponesimod. Posaconazole The metabolism of Idelalisib can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Idelalisib. Pralsetinib The metabolism of Idelalisib can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Idelalisib which could result in a higher serum level. Prednisolone The metabolism of Idelalisib can be increased when combined with Prednisolone. Prednisolone The metabolism of Idelalisib can be increased when combined with Prednisolone acetate. Prednisolone The metabolism of Idelalisib can be increased when combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Idelalisib. Prednisone ace The metabolism of Idelalisib can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Idelalisib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Prilocaine. Primaquine The metabolism of Idelalisib can be decreased when combined with Primaquine. Primidone The metabolism of Idelalisib can be increased when combined with Primidone. Probenecid The metabolism of Idelalisib can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Idelalisib. Progesterone Progesterone may decrease the excretion rate of Idelalisib which could result in a higher serum level. Propafenone The serum concentration of Idelalisib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Proparacaine. Propofol The metabolism of Idelalisib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idelalisib. Prucalopride The metabolism of Prucalopride can be decreased when combined with Idelalisib. Quinidine The metabolism of Idelalisib can be decreased when combined with Quinidine Quinine The metabolism of Idelalisib can be increased when combined with Quinine. Quinupristin The metabolism of Idelalisib can be decreased when combined with Quinupristin. Rabeprazole Rabeprazole may decrease the excretion rate of Idelalisib which could result in a higher serum level. Rabies globulin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Idelalisib. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idelalisib. Rabies antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Idelalisib. Raloxifene The metabolism of Idelalisib can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Idelalisib. Ranolazine The serum concentration of Idelalisib can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Ravulizumab. Regorafenib The metabolism of Regorafenib can be decreased when combined with Idelalisib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Idelalisib. Remdesivir The metabolism of Idelalisib can be decreased when combined with Remdesivir. Repaglinide The excretion of Repaglinide can be decreased when combined with Idelalisib. Reserpine The serum concentration of Idelalisib can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Idelalisib. Revefenacin Idelalisib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Idelalisib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Idelalisib can be increased when combined with Rifabutin. Rifampicin The metabolism of Idelalisib can be increased when combined with Rifampicin. Rifamycin The metabolism of Idelalisib can be increased when combined with Rifamycin. Rifapentine The metabolism of Idelalisib can be increased when combined with Rifapentine. Rilonacept The metabolism of Idelalisib can be increased when combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Idelalisib. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Idelalisib. Riociguat The serum concentration of Idelalisib can be increased when it is combined with Riociguat. Ripretinib Ripretinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Idelalisib is combined with Risankizumab. Ritonavir The serum concentration of Idelalisib can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib. Rivaroxaban The serum concentration of Idelalisib can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Idelalisib can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Idelalisib. Rolapitant Rolapitant may decrease the excretion rate of Idelalisib which could result in a higher serum level. Romidepsin The metabolism of Romidepsin can be decreased when combined with Idelalisib. Ropeginterferon a The risk or severity of adverse effects can be increased when Idelalisib is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Ropivacaine. Rosuvastatin The metabolism of Idelalisib can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Idelalisib. Roxadustat The serum concentration of Idelalisib can be increased when it is combined with Roxadustat. Roxithromycin The metabolism of Idelalisib can be decreased when combined with Roxithromycin. Rubella virus vacc The risk or severity of infection can be increased when Rubella virus vaccine is combined with Idelalisib. Rucaparib The metabolism of Idelalisib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Idelalisib can be increased when combined with Rufinamide. Ruxolitinib The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Idelalisib. Safinamide Safinamide may decrease the excretion rate of Idelalisib which could result in a higher serum level. Sapropterin The serum concentration of Idelalisib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Idelalisib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Idelalisib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Idelalisib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Idelalisib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Idelalisib can be increased when combined with Secobarbital. Secukinumab The metabolism of Idelalisib can be increased when combined with Secukinumab. Selexipag The serum concentration of Selexipag can be increased when it is combined with Idelalisib. Selpercatinib The serum concentration of Selpercatinib can be increased when it is combined with Idelalisib. Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Idelalisib. Sildenafil The serum concentration of Idelalisib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Idelalisib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Idelalisib can be increased when combined with Siltuximab. Simeprevir The metabolism of Idelalisib can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Idelalisib can be increased when it is combined with Simvastatin. Sincalide The excretion of Sincalide can be decreased when combined with Idelalisib. Siponimod The risk or severity of adverse effects can be increased when Idelalisib is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idelalisib. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Idelalisib. Sitagliptin The serum concentration of Idelalisib can be increased when it is combined with Sitagliptin. Sitaxentan The metabolism of Idelalisib can be decreased when combined with Sitaxentan. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Idelalisib. Sofosbuvir The serum concentration of Idelalisib can be increased when it is combined with Sofosbuvir. Somatostatin The metabolism of Idelalisib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Idelalisib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Idelalisib. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Idelalisib. Sotagliflozin Sotagliflozin may decrease the excretion rate of Idelalisib which could result in a higher serum level. Sotorasib The serum concentration of Idelalisib can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Idelalisib is combined with Spesolimab. St. John’s Wort The metabolism of Idelalisib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Idelalisib can be decreased when combined with Stiripentol. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Idelalisib. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Idelalisib. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Idelalisib. Sulfinpyrazone The metabolism of Idelalisib can be increased when combined with Sulfinpyrazone. Sumatriptan The excretion of Sumatriptan can be decreased when combined with Idelalisib. Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Idelalisib. Suvorexant The metabolism of Idelalisib can be decreased when combined with Suvorexant. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib. Tafamidis The serum concentration of Idelalisib can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Idelalisib. Tamoxifen The metabolism of Idelalisib can be increased when combined with Tamoxifen. Tasimelteon The metabolism of Idelalisib can be decreased when combined with Tasimelteon. Taurocholic acid Taurocholic acid may decrease the excretion rate of Idelalisib which could result in a higher serum level. Tazemetostat The metabolism of Idelalisib can be decreased when combined with Tazemetostat. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Idelalisib. Technetium The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Idelalisib. Tecovirimat The metabolism of Idelalisib can be increased when combined with Tecovirimat. Tegaserod The serum concentration of Idelalisib can be increased when it is combined with Tegaserod. Telaprevir The metabolism of Idelalisib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Idelalisib can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Idelalisib which could result in a higher serum level. Telotristat ethyl The serum concentration of Idelalisib can be decreased when it is combined with Telotristat ethyl. You Might Also Read Hyoscine Hydrobromide - Uses, Dosage, Side, Effects, Interaction Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Idelalisib. Temsirolimus The risk or severity of adverse effects can be increased when Temsirolimus is combined with Idelalisib. Teniposide The metabolism of Idelalisib can be decreased when combined with Teniposide. Tenofovir alafe The metabolism of Idelalisib can be decreased when combined with Tenofovir alafenamide. Tenofovir diso The serum concentration of Idelalisib can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Idelalisib can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Idelalisib. Terbinafine The metabolism of Idelalisib can be increased when combined with Terbinafine. Terfenadine The metabolism of Idelalisib can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Idelalisib. Testosterone The metabolism of Idelalisib can be increased when combined with Testosterone. Tetracaine The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Tetracaine. Tetracycline The metabolism of Idelalisib can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Idelalisib. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Idelalisib. Theophylline The metabolism of Theophylline can be decreased when combined with Idelalisib. Thiamylal The metabolism of Idelalisib can be increased when combined with Thiamylal. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Idelalisib. Ticagrelor The metabolism of Idelalisib can be decreased when combined with Ticagrelor. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Idelalisib. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Idelalisib. Tipranavir The metabolism of Idelalisib can be decreased when combined with Tipranavir. Tivozanib Tivozanib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Idelalisib is combined with Tixocortol. Tocilizumab The metabolism of Idelalisib can be increased when combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Idelalisib. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Idelalisib. Topiramate The metabolism of Idelalisib can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Idelalisib. Torasemide The excretion of Torasemide can be decreased when combined with Idelalisib. Toremifene The serum concentration of Idelalisib can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib. Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Idelalisib. Tramadol The metabolism of Tramadol can be decreased when combined with Idelalisib. Trastuzumab Trastuzumab may increase the neutropenic activities of Idelalisib. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Idelalisib. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Idelalisib. Triamcinolone The metabolism of Idelalisib can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Idelalisib can be decreased when combined with Triclabendazole. Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Idelalisib. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Idelalisib. Trilaciclib The serum concentration of Trilaciclib can be increased when it is combined with Idelalisib. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Idelalisib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Idelalisib. Troglitazone The metabolism of Idelalisib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Idelalisib can be decreased when combined with Troleandomycin. Tucatinib Tucatinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Idelalisib. Typhoid Va The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Idelalisib. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Idelalisib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Idelalisib. Umbralisib The serum concentration of Idelalisib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Idelalisib. Upadacitinib The risk or severity of adverse effects can be increased when Idelalisib is combined with Upadacitinib. Valoctocogene The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Idelalisib. Valproic acid The metabolism of Idelalisib can be decreased when combined with Valproic acid. Valsartan The excretion of Valsartan can be decreased when combined with Idelalisib. Vandetanib The metabolism of Vandetanib can be decreased when combined with Idelalisib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Idelalisib. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Idelalisib. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Idelalisib. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Idelalisib. Velpatasvir Velpatasvir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Vemurafenib The serum concentration of Idelalisib can be increased when it is combined with Vemurafenib. Venetoclax The metabolism of Idelalisib can be decreased when combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The metabolism of Idelalisib can be decreased when combined with Verapamil. Vibrioantigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Idelalisib. Vilanterol The risk or severity of adverse effects can be increased when Idelalisib is combined with Vilanterol. Viloxazine The metabolism of Idelalisib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Idelalisib can be increased when combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Idelalisib. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Idelalisib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Idelalisib. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Idelalisib. Vismodegib Vismodegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Vitamin E The metabolism of Idelalisib can be increased when combined with Vitamin E. Voclosporin The risk or severity of adverse effects can be increased when Idelalisib is combined with Voclosporin. Vorapaxar The metabolism of Idelalisib can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Idelalisib can be decreased when combined with Voriconazole. Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Idelalisib. Voxelotor The serum concentration of Idelalisib can be increased when it is combined with Voxelotor. Voxilaprevir Voxilaprevir may decrease the excretion rate of Idelalisib which could result in a higher serum level. Warfarin The serum concentration of Warfarin can be increased when it is combined with Idelalisib. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Idelalisib. Zafirlukast The metabolism of Idelalisib can be decreased when combined with Zafirlukast. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Idelalisib. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Idelalisib. Zimelidine The metabolism of Idelalisib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Idelalisib can be decreased when combined with Ziprasidone. Zonisamide The serum concentration of Idelalisib can be increased when it is combined with Zonisamide. Zopiclone The metabolism of Zopiclone can be decreased when combined with Idelalisib. Zuclopenthixol The metabolism of Idelalisib can be decreased when combined with Zuclopenthixol. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman. Idelalisib was teratogenic in animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Lactation No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound to plasma proteins, the amount in milk is likely to be low. It is sometimes given in combination with rituximab, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during idelalisib therapy and for at least 1 month after the last dose. How should this medicine be used? Idelalisib comes as a tablet to take by mouth. It is usually taken with or without food twice a day. Take idelalisib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take idelalisib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not split, chew, or crush them. Your doctor may decrease your dose of idelalisib or tell you to stop taking the medication for a time or permanently if you experience serious side effects during your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take idelalisib even if you feel well. Do not stop taking idelalisib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before taking idelalisib, tell your doctor and pharmacist if you are allergic to idelalisib, any other medications, or any of the ingredients in idelalisib tablets. If you have ever had a severe allergic reaction in the past, such as swelling of your face, lips or throat; difficulty swallowing or breathing; or peeling, blistering skin, your doctor will probably tell you not to take idelalisib.Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: carbamazepine (Carbatrol, Epitol, Equetro, others); clarithromycin (Biaxin, in PrevPac); itraconazole (Onmel, Sporanox); ketoconazole (Nizoral); medications used to treat human immunodeficiency virus (HIV) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, in Technivie); midazolam; nefazodone; phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus Met, in Duetact, in Oseni); rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with idelalisib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor and pharmacist what herbal products you are taking, especially St. John’s wort. You should not take St. John’s wort during your treatment with idelalisib. tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant during your treatment with idelalisib. You should use birth control to prevent pregnancy during your treatment with idelalisib and at least 1 month after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while taking idelalisib, call your doctor immediately. Idelalisib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed while you are taking idelalisib and for at least one month after your final dose. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205858s014lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Idelalisib https://go.drugbank.com/drugs/DB09054 https://www.drugs.com/mtm/idelalisib.html https://medlineplus.gov/druginfo/meds/a614040.html https://en.wikipedia.org/wiki/Idelalisib https://www.webmd.com/drugs/2/drug-166679/idelalisib-oral/details/list-contraindications https://www.mayoclinic.org/drugs-supplements/idelalisib-oral-route/side-effects/drg-20112990?p=1 https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib https://commonchemistry.cas.org/detail?cas_rn=870281-82-6 https://www.nlm.nih.gov/copyright.html https://chem.nlm.nih.gov/chemidplus/sid/0870281826 https://chem.nlm.nih.gov/chemidplus/sid/1146702546 https://chem.nlm.nih.gov/chemidplus/ https://www.drugbank.ca/legal/terms_of_use https://www.drugbank.ca/drugs/DB09054 https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources https://comptox.epa.gov/dashboard/DTXSID701007266 https://comptox.epa.gov/dashboard/chemical-lists/ https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/244183 https://www.fda.gov/about-fda/about-website/website-policies#linking IDELALISIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YG57I8T5M0 https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8408 http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82701 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology https://www.fda.gov/about-fda/about-website/website-policies#linking IDELALISIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm https://www.nlm.nih.gov/copyright.html Idelalisib https://www.ncbi.nlm.nih.gov/books/n/livertox/Idelalisib/ https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C78825 NCI Thesaurus Tree https://ncit.nci.nih.gov http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2216870/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets http://ctdbase.org/about/legal.jsp idelalisib https://ctdbase.org/detail.go?type=chem&acc=C552946 http://www.dgidb.org/downloads IDELALISIB https://www.dgidb.org/drugs/IDELALISIB https://www.guidetopharmacology.org/about.jsp#license idelalisib https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741 https://www.guidetopharmacology.org/targets.jsp http://idrblab.net/ttd/data/drug/details/D0J5VR https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ https://www.nlm.nih.gov/copyright.html IDELALISIB https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=IDELALISIB https://www.ema.europa.eu/en/about-us/legal-notice Zydelig (EMEA/H/C/003843) https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig https://www.nlm.nih.gov/copyright.html Idelalisib https://www.ncbi.nlm.nih.gov/books/NBK500849/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ https://www.fda.gov/about-fda/about-website/website-policies#linking Zydelig https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page https://www.fda.gov/about-fda/about-website/website-policies#linking IDELALISIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory https://www.cancer.gov/policies/copyright-reuse Idelalisib https://www.cancer.gov/about-cancer/treatment/drugs/idelalisib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html idelalisib https://rxnav.nlm.nih.gov/id/rxnorm/1544460 http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/40L PubChem https://pubchem.ncbi.nlm.nih.gov https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052090-329671522 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052090-329667227 https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052090-329667578 https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052090-826201670 https://creativecommons.org/publicdomain/zero/1.0/ Idelalisib https://www.wikidata.org/wiki/Q5908266 https://www.nlm.nih.gov/copyright.html idelalisib https://www.ncbi.nlm.nih.gov/mesh/67552946 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 Enzyme Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68004791 https://www.kegg.jp/kegg/legal.html USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html https://creativecommons.org/licenses/by/4.0/ https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 391539868 https://pubchem.ncbi.nlm.nih.gov/substance/391539868 SID 427295427 https://pubchem.ncbi.nlm.nih.gov/substance/427295427 References